Site Management Organizations Market by Therapeutic Areas (Oncological Disorders, CNS Disorders, Infectious Diseases, Cardiovascular Diseases and Others), Trial Phase (Phase I, Phase II, Phase III and Phase IV), Clinical Trial Components (Site Management,

Site Management Organizations Market by Therapeutic Areas (Oncological Disorders, CNS Disorders, Infectious Diseases, Cardiovascular Diseases and Others), Trial Phase (Phase I, Phase II, Phase III and Phase IV), Clinical Trial Components (Site Management, Onsite Monitoring, Project Management and Others), Type of Interventions (Therapeutics, Devices and Surgical Procedure) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2021-2035

Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78 billion annually. However, the conduct of such trials is often fraught with challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines. Further, owing to the inherent complexity of the overall process and involvement of several different stakeholders, these trials are prone to delays. In fact, over 80% of the clinical trials are delayed by at least one to six months, while only 10% of the studies are completed on time. Therefore, innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers. The advantages of engaging such specialized service providers are numerous and enable sponsors to meet their clinical research timelines. In addition, SMOs can facilitate rapid patient recruitment, reduce study timelines, and manage the entire clinical trial processes and administrative work for their clients. Moreover, drug / medical device developers, and even the contract research organizations (CROs), can employ the therapeutic and operational expertise, global site networks and well-established processes and tools offered by SMOs in order to carry out their clinical research and site management activities in a cost and time efficient manner.

Currently, around 250 companies claim to be actively providing clinical site management services to drug and medical device developers across the world. Recently, there has been a lot of activity within the site management market, primarily focused on consolidation of affiliated capabilities, service portfolio expansions and collaborations to extend geographical reach. The aforementioned developments may be attributed to the growing preference for one-stop-shops among sponsor companies, and the gradual acceptance of outsourcing as a viable and beneficial operating model for conducting clinical trials and managing research sites. With the growing complexity, as well as rise in the number of clinical trials being registered, the demand for SMOs is anticipated to grow at a steady pace in the coming years.

SCOPE OF THE REPORT
The ‘Site Management Organizations Market – Distribution by Therapeutic Areas (Oncological Disorders, CNS Disorders, Infectious Diseases, Cardiovascular Diseases and Others), Trial Phases (Phase I, Phase II, Phase III and Phase IV), Clinical Trial Components (Site Management, Onsite Monitoring, Project Management and Others), Type of Interventions (Therapeutics, Devices and Surgical Procedure) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2021-2035’ report features an extensive study of the current market landscape and future potential of the site management organizations market. The study features an in-depth analysis, highlighting the capabilities of clinical trial site management service providers engaged in this domain. Amongst other elements, the report features:
 A detailed review of the overall landscape of companies offering clinical trial site management services to various organizations, including CROs, and pharmaceutical, biotechnology and medical devices companies, along with information on their year of establishment, company size (in terms of employee count), location of headquarters and geographical reach of the companies. The chapter also covers details related to type of service(s) offered (site identification and selection, study feasibility, study protocol development, patient recruitment, patient retention, project management, regulatory support, clinical monitoring, site management, clinical trial data management, patient follow-up, real-time enquiry / information support, study contract, budget and expense management / contract negotiation, hiring / training study investigator, logistics management, quality control and quality assurance and others) and therapeutic expertise of service providers.
 An insightful 2×2 representation of the competitiveness analysis of various service providers segregated into three peer groups based on location of their headquarters (North America, Europe, and Asia-Pacific and RoW). The companies were further distributed across the geographies, based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large (>500 employees), highlighting the top players in this domain, based on their respective capabilities.
 An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021 (till August). The various types of partnerships captured in our study include (in alphabetical order) acquisitions, clinical trial agreements, clinical trial site agreements, joint ventures, mergers, product / technology integration agreements, research agreements, service alliances, technology licensing agreements, technology utilization agreements and other related agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, focus area and most active players (in terms of number of partnerships). It also highlights the regional distribution of the collaborations.
 A detailed analysis of various investments received by players engaged in this domain during the period 2015-2021 (till August), based on several relevant parameters, such as year of investment, number of funding instances, amount invested, type of funding (grant, seed, venture capital, secondary offering, other equity, debt and others) and type of investor, along with information on the most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and geographical distribution (in terms of number of funding instances and amount invested).
 An in-depth analysis of completed, ongoing and planned clinical studies during the period 2016-2021 (till August), to present clinical trial key insights, based on several relevant parameters, such as trial registration year, number of enrolled patients, trial status, trial phase, type of sponsor and geographical distribution of number of trials and enrolled patient population.
 An informed estimate of the annual demand for clinical study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
 Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) that offer various clinical trial site management services, across North America, Europe and Asia-Pacific. Each profile provides an overview of the company, featuring information on the year of establishment, number of employees, location of their headquarters, details related to its site management service portfolio, recent developments, and an informed future outlook.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the site management organizations market over the coming decades. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] therapeutic areas (oncological disorders, CNS disorders, infectious diseases, respiratory disorders, cardiovascular diseases, endocrine disorders, gastrointestinal disorders, musculoskeletal diseases, immunological disorders and others), [B] clinical trial phases (phase I, phase II, phase III and phase IV), [C] clinical trial components (site management, onsite monitoring, project management, data management, regulatory affairs, logistics, quality control and others), [D] types of interventions (therapeutics, devices and surgical procedure) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and RoW). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:
 Vinod Gyanchandani (Country Head - Clinical Operations, GDD Experts)
 Marisa Vico (Medical Director and Operations Manager, SMO – Dra. Marisa Vico)
 Eugene Winifred (Project Manager, Syncretic Clinical Research Services)

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED
 Who are the leading players in the clinical trial site management domain?
 What is the relative competitiveness of different site management organizations?
 What type of partnership models are commonly adopted by stakeholders in this industry?
 What is the capital investments trend in site management organizations domain?
 Which are the most active clinical trial centers?
 What are the major market trends and driving factors that are likely to impact the growth of site management organizations market?
 How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the site management organizations market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to SMOs, featuring information on their working model and major differences between a SMO and CRO. Further, it provides details related to the various services offered by SMOs. Additionally, it highlights the advantages offered by SMOs acting as one-stop-shops. The chapter concludes with a discussion on the anticipated opportunity areas for SMOs and inputs on their projected growth in the coming years.

Chapter 4 features a detailed review of the current market landscape of around 250 companies offering clinical trial site management services. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also covers details about type of site management service(s) offered (site identification and selection, study feasibility, study protocol development, patient recruitment, patient retention, project management, regulatory support, clinical monitoring, site management, clinical trial data management, patient follow-up, real-time enquiry / information support, study contract, budget and expense management / contract negotiation, hiring / training study investigator, logistics management, quality control and quality assurance and others), therapeutic expertise of service providers (oncological disorders, CNS disorders, infectious diseases, respiratory disorders, cardiovascular diseases, endocrine disorders, gastrointestinal disorders, musculoskeletal diseases, immunological disorders, dermatological disorders and others) and geographical reach of the companies.

Chapter 5 presents an insightful competitiveness analysis of the site management organizations, located in North America, Europe and Asia-Pacific. The companies are further segmented based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large (>500 employees) across these geographies. The analysis compares the service providers on the basis of various parameters, such as site management services offered, therapeutic expertise, geographical reach and year of establishment. In the chapter, stakeholder entities have been plotted on a 2×2 matrices, having a company’s experience (based on its year of establishment) (abscissa) and company competitiveness (ordinate) as the two axes.

Chapter 6 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in offering clinical trial site management services in North America. Each profile provides an overview of the company, information related to its site management service portfolio, and details on recent developments, as well as an informed future outlook.

Chapter 7 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in offering clinical trial site management services in Europe. Each profile provides an overview of the company, information related to its site management service portfolio, and details on recent developments, as well as an informed future outlook.

Chapter 8 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in offering clinical trial site management services in Asia-Pacific. Each profile provides an overview of the company, information related to its site management service portfolio, and details on recent developments, as well as an informed future outlook.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021 (till August). It includes a brief description of the partnership models (including service alliances, clinical trial agreements, acquisitions, product / technology integration agreements, technology utilization agreements, R&D agreements, mergers, joint ventures, clinical trial site agreements, technology licensing agreements and others) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of agreement, type of agreement, focus area and most active player(s) (in terms of number of partnerships inked). Further, the chapter includes a world map representation of all the deals inked in this field in the period 2016-2021, highlighting both intercontinental and intracontinental partnership activity.

Chapter 10 presents details on various investments received by various players engaged in clinical trial site management domain. It also includes an analysis of the funding instances that have taken place in the market, during the period 2015-2021 (till August), highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 11 provides a detailed analysis of completed, ongoing, and planned clinical studies during the period 2016-2021 (till August), to present clinical trial key insights, highlighting prevalent trends across various relevant parameters, such as trial registration year, number of enrolled patients, trial status, trial phase, type of sponsor and geographical distribution of number of trials and enrolled patient population.

Chapter 12 provides an informed estimate of the annual demand for clinical study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the site management organizations market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] therapeutic areas (oncological disorders, CNS disorders, infectious diseases, respiratory disorders, cardiovascular diseases, endocrine disorders, gastrointestinal disorders, musculoskeletal diseases, immunological disorders and others), [B] clinical trial phases (phase I, phase II, phase III and phase IV), [C] clinical trial components (site management, onsite monitoring, project management, data management, regulatory affairs, logistics, quality control and others), [D] types of interventions (therapeutics, devices and surgical procedure) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and RoW).

Chapter 14 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the site management domain. In this chapter, we have presented the details of our conversation with Vinod Gyanchandani (Country Head - Clinical Operations, GDD Experts), Marisa Vico (Medical Director and Operations Manager, SMO – Dra. Marisa Vico) and Eugene Winifred (Project Manager, Syncretic Clinical Research Services).

Chapter 16 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.

1. 3H Medi Solution
2. 3S Pharma
3. Accel Clinical Services
4. Accell Clinical Research
5. Accelovance
6. accerise
7. Access Clinical Research
8. Ace Research
9. ACI Clinical
10. Acrostar SMO
11. ACTG-CRO
12. Advanced Clinical
13. Aetion
14. Affiliated Clinical Research
15. AiCure
16. Alpha Oncology Research (AOR)
17. Altasciences
18. Amadeus Capital Partners
19. AmberCRO
20. American Liver Foundation
21. American Research Associates (ARA)
22. AmerisourceBergen
23. Analgesic Solutions
24. Andronovo Labs
25. Anteris Bio
26. Antev
27. Antidote
28. AOBiome Therapeutics
29. Apex Medical Research
30. APF Research
31. ApotheCom
32. Apptomics
33. Aptitude Health
34. Ardent Clinical Research Services
35. Asian Eye Institute
36. Associated Medical
37. Association of Clinical Research Professionals (ACRP)
38. AstraZeneca
39. Atlant Clinical
40. Aurum Clinical Research
41. AusTrials
42. AutoCruitment
43. Avacare
44. AXELLE Group
45. AXIM Biotechnologies
46. BBK Worldwide
47. Beijing Aisimo Medical Science and Technology
48. Beijing CTSMED
49. Beijing EasyTrial MedTech
50. Beijing Global Pharmaceutical Research (Acquired by EPS International)
51. Beijing Illness Challenge Foundation (ICF)
52. Best Clinical Practice
53. Bioclinica
54. Biomapas
55. Biomedical Advanced Research and Development Authority (BARDA)
56. Biomic Lifescience
57. Biosite Research
58. Box
59. BrainStorm Cell Therapeutics
60. Briban Invest
61. Bridge Clinical Research
62. BTC Network
63. Cactus Clinical Research
64. Calmark
65. Canadian Centre for Clinical Trials (CCCT)
66. Cardialysis
67. CaringKind
68. Caris Life Sciences
69. Carpathian Research
70. Catalyst Regulatory Services (Acquired by Veristat)
71. CCT Research
72. Central India Clinical Research Services (CICRS)
73. Centre International de Développement Pharmaceutique (CIDP)
74. Chase Medical Research
75. ChiG
76. Chrondel
77. Cidara Therapeutics
78. Cinven
79. Clariness
80. Cliantha Research
81. Clin Sol
82. CLINADE
83. Clinart MENA
84. ClinChoice
85. ClinEdge
86. Clinerion
87. Clinexa Life Sciences
88. Clinical Accelerator
89. Clinical Development Solutions (CDS)
90. Clinical Endpoints
91. Clinical Investigation Centre (University Malaya Medical Centre)
92. Clinical Research Fastrack
93. Clinical Research Partners
94. Clinical Trial Networking (CT-N)
95. Clinical Trials Management Solutions (CTMS)
96. ClinicalConnection
97. Clinipace
98. CLINISYD
99. Clinixir
100. ClinROtech
101. ClinSmart
102. Clinsol
103. Clinspire Research
104. Clintec
105. Clintract
106. ClinVax
107. Clinverse
108. ClinWin Research Services
109. CLS-Ukraine
110. CluePoints
111. CMIC Group
112. CMX Research
113. CNS Pharmaceuticals
114. COD Research
115. Comac Medical
116. COMPASS Pathways
117. Compass Research
118. Continuum Clinical
119. Cosmic Clinical Services
120. Credevo
121. Crestline Investors
122. CRO Pharmatrendz
123. Croissance Clinical Research
124. CROMSOURCE
125. CRS Clinical Research Services
126. CTC North
127. CTI Clinical Trial and Consulting Services
128. CTM
129. CX Partners
130. Cyclo Therapeutics
131. Cytespace
132. DAC Patient Recruitment Services
133. Datavant
134. DAVA Oncology
135. DaVita Clinical Research
136. Deep Lens
137. Deerfield Management
138. DEMEDICA
139. Devana Solutions
140. DFnet
141. Dimension Research
142. Direct Biologics
143. dMed
144. Duke Clinical Research Institute (DCRI)
145. eClinical Solutions
146. Edenwell Therapeutics
147. EDETEK
148. Effectus CTR
149. EGeen
150. Elligo Health Research
151. EMMES
152. emovis
153. Empower Capital
154. EPS Associates
155. EPS International
156. EQT
157. ERT
158. ESTERN Medical
159. Estudios Clínicos Latinoamérica (ECLA)
160. Ethicscare Clinical Research Services (ECRS)
161. EthosExcel
162. Everest Clinical Research
163. Evolution Research Group (ERG)
164. Experior
165. F2 Ventures
166. FARMEPO
167. FDAMap
168. Febo
169. FedDev Ontario
170. FHI Clinical
171. Fidelis Research
172. FOMAT Medical Research
173. Foundation Medicine
174. Free to Breathe
175. Frenova Renal Research
176. Fresenius Medical Care
177. Gaea
178. Gama CRO
179. GB Sciences
180. GCP Clinical Studies
181. GCP Research
182. G-CURE Healthcare
183. GDD Experts
184. Genentech
185. General Atlantic
186. George Clinical
187. GIC
188. Global Clinical Trials
189. Goldman Sachs Asset Management International (GSAMI)
190. Gratisol Labs
191. GSK
192. GuideStar Research
193. Haihe Biopharma
194. Hatteras Venture Partners
195. Haxon Life Sciences
196. Healing Hands Clinical Research Services (HHCRS)
197. HealthVerity
198. Horizon Research
199. Hospital Alemão Oswaldo Cruz
200. EI Hospital de Especialidades Teodoro Maldonado Carbo
201. Hoth Therapeutics
202. hyperCORE International
203. I’rom Group
204. iCo Therapeutics
205. iDD Research Solutions
206. IKCON PHARMA
207. Illingworth Research Group
208. InClin
209. Incred CR
210. Indian Institute of Clinical Research & Management (IICRM)
211. Industrifonden
212. Infectious Disease Research Institute (IDRI)
213. InformedDNA
214. Innoplexus
215. Innovaderm
216. Innovate Research
217. Insignia Clinical Services (ICS)
218. INSPIRE
219. Integrity Capital Wealth Management
220. Inteliquet
221. International Research Networks (IRN)
222. Intouch Clinical Research Center
223. Intrinsic Imaging (Acquired by WCG)
224. Invicro
225. IPHARMA
226. IQVIA
227. ITOCHU
228. ITOCHU Technology Ventures
229. Johnson Clinical Research
230. Juno Research
231. Karyopharm Therapeutics
232. Klinar CRO
233. KlinEra
234. KMR Group
235. Komplett Clinical Research (KCR)
236. KPS Clinical Services
237. KV Clinical Research Services (KVCR)
238. Kyung Hee University Hospital
239. LEADS Clinical Research and Bio Services
240. Limbix
241. Linical Americas
242. Link Health
243. LITMUS
244. LiveRamp
245. LMC Manna Research
246. Lyft
247. MakroCare
248. Marshfield Clinic Research Institute
249. Mary Bird Perkins Cancer Center
250. Mayo Clinic
251. med fusion (Acquired by Quest Diagnostics)
252. Medable
253. MedAvante-ProPhase (Acquired by WCG)
254. MEDEX
255. Median Technologies
256. Medicor Research
257. Medicus Alliance
258. Medicus Health Partners
259. Medidata
260. Melanoma Research Alliance
261. MENE Health Group
262. Merck
263. Merck Global Health Innovation Fund (GHI)
264. Metrics Champion Consortium (MCC) (Acquired by WCG)
265. Mitsui
266. MMG
267. Molecular Templates
268. Montserrat Day Hospitals
269. MPM Capital
270. MPR
271. MTIP
272. Muscular Dystrophy Association (MDA)
273. National Cancer Center
274. National Institute of Clinical Research (NICR)
275. National Taiwan University Hospital (NTUH)
276. NeoGenomics
277. Newton Clinical Research
278. NextPhase Research
279. Nomad Life Sciences
280. North Estonia Medical Centre
281. Novotech
282. nRollmed
283. Nucleon Therapeutics
284. O4 Research
285. Oaxaca Site Management Organization (OSMO)
286. Octopus Investments
287. Octopus Ventures
288. Okogen
289. OneOncology
290. Optimum CRO
291. Ora
292. Oracle
293. orphan reach
294. Orphanos
295. Ospedale San Raffaele
296. P3 Research
297. Panthera
298. Parallel 6 (Acquired by PRA Health Sciences)
299. Parexel
300. PAS Research
301. PatientPoint
302. Peachtree
303. Penta ID Innovation
304. Pepgra
305. Pfizer
306. Pharmatech
307. Pharm-Olam
308. phaware
309. Physicians Research Group (PRG)
310. Plexus Research
311. Polaris Biopharma Consulting
312. PPC
313. PPD
314. Prabhans Clinical Services
315. Praxis
316. Precision for Medicine
317. Precision Health
318. Prime Site
319. Prodia
320. Protocol First
321. ProTrials Research
322. Prudentia
323. Psilera
324. Puerto Rico Consortium for Clinical Investigation (PRCCI)
325. Pulse Clinical Research
326. Pusan National University Hospital (PNUH)
327. PWNHealth
328. QAscent Research Solutions
329. QPS
330. Quad-C Management
331. Quanticate
332. Quantime World
333. Quest Diagnostics
334. Quintessential Solutions
335. Ravek
336. RealTime Software Solutions
337. Red Maple Trials
338. RemediumOne
339. Research Trials Group
340. RESolutions
341. Reumalab
342. Revive Therapeutics
343. Richmond Behavioral Associates (RBA)
344. Rock Springs Capital
345. Rutherford Health plc
346. S4 Research
347. Sabre Partners
348. Samahitha Research Solutions
349. Sandia Clinical Research
350. Sanjeevani
351. Sanofi
352. Santa Maria Gastroenterology
353. Scandinavian CRO
354. S-Clinical
355. SDS Clinical
356. Sequoia Capital
357. SGS Life Science Services
358. Shanghai Shoujia Medical Clinical Research
359. SiChaGi Medical Solutions
360. SIGAL SMS
361. Signify Health
362. SitePartner
363. Skin Research Institute of Singapore (SRIS)
364. Skylight Health
365. Smedvig Capital
366. SMO – DRA. MARISA VICO
367. SMO Clinical Research (SMO-India)
368. SMO ClinPlus
369. SMO UCT
370. SMOconnect
371. Smooth Drug Development
372. SMO-Pharmina
373. Society for Clinical Research Sites
374. Solutions OP
375. Somaya Research and Health Services
376. SoMex Research & Health Organisation
377. Sonic Clinical Trials
378. Spectral Medical
379. Spectrum Clinical Research
380. Spero Oncology (Acquired by Veristat)
381. SPRI Ukraine
382. Springhill Fund
383. SQN Clinical
384. Statistics Collaborative
385. Superstring Capital
386. Surescripts
387. Syncretic Clinical Research Services
388. Syneos Health
389. Syntax
390. Synteract
391. Syreon
392. Takeda Pharmaceutical
393. Terveystalo
394. TFS
395. Association of Clinical Research Professionals (ACRP)
396. The Buffalo-Niagara Clinical Alliance (BNCA)
397. The Clinical Trial Company (TCTC) (Acquired by Veristat)
398. The Clinic'les
399. THREAD
400. ThreeWire
401. Tigermed
402. Tiziana Life Sciences
403. Topstone Research
404. Total Clinical Trial Management
405. Translational Research in Oncology (TRIO)
406. Trial Management Group (TMG)
407. Trialbee
408. TrialSpark
409. Trifecta (acquired by WCG)
410. TriNetX
411. Triumph Research Intelligence (TRI)
412. Triumpharma
413. United States Department of Defense (DOD)
414. uMotif
415. Unicorn Protego Site Management Organization (UP SMO)
416. United BioSource (UBC)
417. University of Yamanshi
418. Urgent Care Clinical Trials
419. Vector Oncology
420. Veeda
421. Veeva Systems
422. VeraSci
423. Veristat
424. Vicore Pharma
425. Vigilare International
426. Viomedo
427. Virgo
428. Walter and Eliza Hall Institute of Medical Research (WEHI)
429. WCCT Global
430. WCG
431. WCG Avoca
432. WCG PharmaSeek
433. WindRose Health Investors
434. Worldwide Clinical Trials
435. WuXi Clinical (a WuXi AppTec Company)
436. Xcene Research
437. Xylem
438. Zagvo Portal
439. ZARTA LIFE
440. Zosano Pharma2-BBB Medicines

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.